Nintedanib Teva

Nintedanib, the active ingredient in Nintedanib Teva, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats idiopathic pulmonary fibrosis and systemic sclerosis‑associated interstitial lung disease in adult patients.

GNH USA supplies Nintedanib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nintedanib is an antifibrotic agent used in fibrotic lung diseases.

- Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: improves lung capacity and delays worsening. - Progressive fibrosing interstitial lung disease: provides benefit in patients with a fibrotic phenotype when other treatments are insufficient.

Nintedanib may cause a range of adverse reactions, most of which are manageable with supportive care.

Common Side Effects: - Nausea - Diarrhea - Vomiting - Abdominal pain - Decreased appetite - Headache

Serious or Rare Side Effects: - Elevated liver enzymes (hepatotoxicity) - Bleeding events - Cardiovascular complications (e.g., myocardial infarction) - Severe infections - Gastrointestinal perforations - Severe skin reactions (e.g., Stevens‑Johnson syndrome)

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for known safety concerns.

- Liver function monitoring: assess transaminases before starting and periodically during therapy. - Bleeding risk: avoid concomitant anticoagulants unless medically necessary. - Cardiovascular assessment: monitor for hypertension or ischemic events. - Gastrointestinal symptoms: manage nausea and diarrhea proactively. - Pregnancy and lactation: use only if benefits outweigh risks; consult physician. - Store at room temperature: keep in original container, protect from moisture and light.

Nintedanib can interact with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase nintedanib exposure. - Anticoagulants: heightened bleeding risk. - P‑gp inhibitors: may raise plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers: may reduce efficacy. - Moderate CYP3A4 inhibitors (e.g., ketoconazole): may modestly increase exposure. - Diuretics: monitor electrolytes and renal function. - Antifungal agents: assess for additive hepatic effects. - NSAIDs: evaluate bleeding risk.